Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-26
2005-04-26
LeGuyader, John L. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000, C536S023100, C536S024500
Reexamination Certificate
active
06884787
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of transforming growth factor-beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding transforming growth factor-beta 3. Methods of using these compounds for modulation of transforming growth factor-beta 3 expression and for treatment of diseases associated with expression of transforming growth factor-beta 3 are provided.
REFERENCES:
patent: 5214136 (1993-05-01), Lin et al.
patent: 5650494 (1997-07-01), Cerletti et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 6110667 (2000-08-01), Lopez-Nieto et al.
patent: WO 9425588 (1994-11-01), None
patent: WO 9840747 (1998-09-01), None
patent: WO 9963975 (1999-12-01), None
Chai, Y et al. Developmental Biology (1994) 162:85-103.*
Liu, J. et al. Developmental Dynamics (2000) 217:343-360.*
Caniggia, I. et al. Journal of Clinical Investigation (1999) 103(12):1641-1650.*
Dijke, P.T. et al. Proc. Nat'l Acad. Sci. (1988)85:4715-4719.*
Yee, W. et al. Am. J. Phys. (1996) 270(14) L992-L1001.*
Braasch, D. A. Biochemistry. Apr. 2002; 41(14): 4503-4510.*
Branch, A. D., (1998). Trends Biochem Sci. Feb. 1998;23(2):45-50.*
Agrawal, S. Trends Biotechnol. Oct. 1996;14(10):376-87.*
Gerwirtz et al., Proc. Natl. Acad. Sci. v 93, pp. 3161-3163.*
Tamm, I. et al. The Lancet. Aug. 2001, 358: 489-497.*
Chai, Y et al. Developmental Biology (1994) 162:85-103.*
Liu, J. et al. Developmental Dynamics (2000) 217:343-360.*
Caniggia, I. et al. Journal of Clinical Investigation (1999) 103(12):1641-1650.*
Dijke, P.T. et al. Proc. Nat'l Acad. Sci. (1988)85:4715-4719.*
Yee, W. et al. Am. J. Phys. (1996) 270(14) L992-L1001.*
Duke et al., “Identification of another member of the transforming growth factors type β gene family”, Proc. Natl. Acad. Sci. USA 1988 85:4715-4719.
Abou-Shady et al.,Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma, Am. J. Surg.,1999, 177:209-215.
Ardley et al.,Fine mapping of 12 previously unassigned EST clones to individual YACs in the familial Alzheimer's disease(FAD)region of chromosome 14q24.3, Cytogenet. Cell Genet.,1998, 82:107-109.
Caniggia et al.,Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies, J. Clin. Invest.,1999, 103:1641-1650.
Chai et al.,Specific transforming growth factor-beta subtypes regulate embryonic mouse Meckel's cartilage and tooth development, Dev. Biol.,1994, 162:85-103.
Crowe et al.,Delayed wound healing in immunodeficient TGF-beta 1 knockout mice, J. Invest. Dermatol.,2000, 115:3-11.
Ghellal et al.,Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma, Anticancer Res.,2000, 20:4413-4418.
Kaartinen et al.,Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction, Nat. Genet.,1995, 11:415-421.
Liu et al.,Transforming growth factor beta2, but not beta1 and beta3, is critical for early rat lung branching, Dev. Dyn.,2000, 217:343-360.
Markowitz,Atherosclerosis, just another cancer?, J. Clin. Invest.,1997, 100:2143-2145.
Nakajima et al.,An Autocrine Function for Transforming Growth Factor(TGF)-b3 in the Tranformation of Atrioventricular Canal Endocardium into Mesenchyme during Chick Heart Development, Developmental Biology,1998, 194:99-113.
Pasche,Role of tranforming growth factor beta in cancer, J. Cell Physiol.,2001, 186:153-168.
Piek et al.,Specificity, diversity, and regulation in TGF-beta superfamily signaling, Faseb J.,1999, 13:2105-2124.
Romitti et al.,Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette smoking and alcohol consumption: evaluation of genotype-environment interactions from a population-based case-control study of orofacial clefts, Teratology,1999, 59:39-50.
Rosier et al.,The potential role of transorming growth factor beta in fracture healing, Clin. Orthop.,1998, S294-300.
Schuppan et al.,Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets?, Acta Gastroenterol. Belg.,2000, 63:366-370.
ten Dijke et al.,Identification of another member of the transforming growth factor type beta gene family, Proc. Natl. Acad. Sci. U. S. A.,1988, 85:4715-4719.
Yee et al.,Glucocorticoid-induced tropoelastin expression is mediated via transforming growth factor-beta 3, Am. J. Physiol.,1996, 270:L992-1001.
Freier Susan M.
Monia Brett P.
ISIS Pharmaceuticals Inc.
LeGuyader John L.
Licata & Tyrrell P.C.
Schultz James Douglas
LandOfFree
Antisense modulation of transforming growth factor-beta 3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of transforming growth factor-beta 3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of transforming growth factor-beta 3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3410563